- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05563142
Venous Vascular Closure System Versus Manual Compression Following Single Shot Device AF Ablation (Style-AF)
November 22, 2022 updated by: Prof. Roland Richard Tilz, University of Luebeck
Venous Vascular Closure System Versus Manual Compression Following Single Shot Device AF Ablation - the Style-AF Study
Prospective, randomized, controlled, multi-center study to compare the safety and efficacy of the Perclose ProStyle suture-mediated closure device (PPS) as to manual compression (MC) for venous hemostasis following single shot device (SSD) based pulmonary vein isolation (PVI).
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Detailed Description
The aim of this study is to show that the time to ambulation after PVI can be reduced by deploying vascular closure device versus manual compression and a figure-of-8 suture only.
Safety, efficacy and feasibility of the PPS device should be proven, too.
Study Type
Interventional
Enrollment (Anticipated)
100
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Nordrhein-Westfalen
-
Bad Oeynhausen, Nordrhein-Westfalen, Germany, 32545
- Not yet recruiting
- Herz- und Diabeteszentrum Nordrhein-Westfalen
-
Contact:
- Phillip Sommer, Prof. Dr. med.
- Phone Number: 1327 +49573197
- Email: psommer@hdz-nrw.de
-
-
Sachsen
-
Leipzig, Sachsen, Germany, 04289
- Not yet recruiting
- Herzzentrum Leipzig
-
Contact:
- Gerhard Hindricks, Prof. Dr. med.
- Phone Number: +49341865
- Email: rhythmo.herzzentrum@helios-gesundheit.de
-
-
Schleswig-Holstein
-
Kiel, Schleswig-Holstein, Germany, 24105
- Not yet recruiting
- Klinik fur Innere Medizin III
-
Contact:
- Evgeny Lyan, Dr. med.
- Phone Number: 22810 +49431500
- Email: evgeny.lyan@uksh.de
-
Luebeck, Schleswig-Holstein, Germany, 23538
- Recruiting
- Klinik für Rhythmologie
-
Contact:
- Roland R Tilz, Prof. Dr.med
- Phone Number: 44533 0049451500
- Email: roland.tilz@uksh.de
-
Contact:
- Claudia Breithaupt
- Phone Number: 44672 0049451500
- Email: claudia.breithaupt@uksh.de
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
16 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Patients age >18
- Elective catheter ablation for atrial fibrillation using a 6 to 14 Fr inner diameter introducer sheath with a minimum of 1 and maximum of 2 femoral venous access sites
Exclusion Criteria:
- Active systemic or cutaneous infection, or inflammation in vicinity of the groin
- Platelet count < 100,000 cells/mm3
- BMI > 45 kg/m2 or < 20 kg/m2
- Attempted femoral arterial access or inadvertent arterial puncture
- Procedural complications that interfered with routine recovery, ambulation, or discharge times
- Incorrect sheath placement
- Intraprocedural bleeding or thrombotic complications
- Access site-specific eligibility criteria to exclude problems with gaining access or location of sheath
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Group Perclose ProStyle closure
50 patients treated with Perclose ProStyle suture-mediated closure device to achieve hemostasis
|
patients will be randomized to either group 1 or group 2 in a 1:1 ratio:
|
Active Comparator: Group manual compression
50 patients treated with manual compression and one figure of eight suture
|
patients will be randomized to either group 1 or group 2 in a 1:1 ratio:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Time to ambulation
Time Frame: 6 hours
|
elapsed time between removal of the final closure device or removal of the final sheath and when the patient can stand and walk 20 ft without evidence of venous re-bleeding from the femoral access site.
|
6 hours
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
total post procedure time
Time Frame: 6 hours
|
elapsed time between removal of the last procedural device for the index procedure and when the patient was able to successfully ambulate
|
6 hours
|
time to hemostasis
Time Frame: 6 hours
|
elapsed time between removal of the closure device or the sheath and first observed and confirmed venous hemostasis, for each access site
|
6 hours
|
time to discharge eligibility
Time Frame: 3 days
|
elapsed time between removal of the final closure device or final sheath and when the patient was eligible for hospital discharge based solely on the assessment of the access site, as determined by the medical team
|
3 days
|
time to discharge
Time Frame: 3 days
|
elapsed time between removal of the final closure device or final sheath and when the patient was discharged from the institution
|
3 days
|
time to closure eligibility
Time Frame: 6 hours
|
elapsed time between removal of the last procedural device for the index procedure and removal of the first closure device or first sheath
|
6 hours
|
Incidence of major adverse events
Time Frame: 30 days
|
Incidence of major adverse events within 30 days after the procedure
|
30 days
|
Incidence of minor adverse events
Time Frame: 30 days
|
Incidence of minor adverse events within 30 days after the procedure
|
30 days
|
Time to final hemostasis
Time Frame: 3 days
|
Attainment of final hemostasis at all venous access sites and freedom from major venous access site closure-related complications
|
3 days
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
November 22, 2022
Primary Completion (Anticipated)
October 6, 2023
Study Completion (Anticipated)
December 31, 2023
Study Registration Dates
First Submitted
September 27, 2022
First Submitted That Met QC Criteria
September 30, 2022
First Posted (Actual)
October 3, 2022
Study Record Updates
Last Update Posted (Actual)
November 23, 2022
Last Update Submitted That Met QC Criteria
November 22, 2022
Last Verified
November 1, 2022
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- Style-AF
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Undecided
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Atrial Fibrillation
-
Ablacon, Inc.CompletedArrhythmias, Cardiac | Atrial Fibrillation, Persistent | Persistent Atrial Fibrillation | Longstanding Persistent Atrial FibrillationGermany
-
Ablacon, Inc.RecruitingAtrial Fibrillation | Arrhythmias, Cardiac | Arrhythmia | Atrial Flutter | Atrial Fibrillation, Persistent | Atrial Tachycardia | Atrial Arrhythmia | Atrial Fibrillation Paroxysmal | Atrial Fibrillation, Paroxysmal or PersistentUnited States, Belgium, Netherlands, Czechia
-
Barts & The London NHS TrustAtriCure, Inc.Not yet recruitingAtrial Fibrillation, Persistent | Persistent Atrial Fibrillation | Atrial Arrhythmia | Atrium; FibrillationUnited Kingdom
-
AtriCure, Inc.Active, not recruitingPersistent Atrial Fibrillation | Atrial Fibrillation (AF) | Longstanding Persistent Atrial FibrillationUnited States
-
Maastricht University Medical CenterRWTH Aachen UniversityUnknownAtrial Fibrillation (Paroxysmal) | Atrial Fibrillation Recurrent | Atrial Fibrillation Common Gene VariantsNetherlands
-
Adagio MedicalRecruitingAtrial Fibrillation | Atrial Flutter | Paroxysmal Atrial Fibrillation | Persistent Atrial FibrillationNetherlands, Germany, Belgium
-
Vivek ReddyEnrolling by invitationAtrial Fibrillation and Flutter | Atrial Flutter Typical | Atrial Fibrillation, Paroxysmal or PersistentUnited States
-
Fundació Institut de Recerca de l'Hospital de la...RecruitingAtrial Arrhythmia | Atrial Fibrillation and Flutter | Atrial Fibrillation RecurrentSpain
-
Abbott Medical DevicesRecruitingAtrial Fibrillation | Paroxysmal Atrial Fibrillation | Persistent Atrial Fibrillation | Atrial ArrhythmiaUnited States, Australia, Belgium, Germany, Spain, Netherlands, France, Austria, Canada, Czechia, Italy, United Kingdom
-
St. George's Hospital, LondonRecruitingAtrial Fibrillation | Atrial Fibrillation, Persistent | Persistent Atrial Fibrillation | Atrial ArrhythmiaUnited Kingdom
Clinical Trials on deploying vascular closure device versus manual compression
-
Medstar Health Research InstituteCardinal HealthCompletedCardiac Diagnostic Procedure | Cardiac Interventional Procedure | Femoral Access Site ClosureUnited States
-
Cordis CorporationCompletedCoronary Arteriosclerosis | Angioplasty, Transluminal, Percutaneous Coronary | Peripheral ArteriosclerosisUnited States
-
Aarhus University Hospital SkejbyVingmed Danmark A/SCompleted
-
Cardiva Medical, Inc.CompletedSurgical WoundUnited States, Australia
-
Frank SaltielBorgess Medical Center; Borgess Cardiology Group; Borgess Heart Center for ExcellenceTerminatedCoronary Artery DiseaseUnited States
-
Erasmus Medical CenterCompletedAortic Valve StenosisNetherlands
-
University of FloridaAccess Pharmaceuticals, Inc.Completed
-
Irmandade Santa Casa Misericórdia MaríliaCompleted
-
Essential Medical, Inc.CompletedFemoral Arteriotomy ClosureNetherlands, Italy
-
Essential Medical, Inc.TeleflexTerminated